Replies to post #143804 on Biotech Values

[biotech jim]

Could MK-6096 be developed for insomnia if suvorexant hits a snag?

Absolutely, but the discussion today was pretty bullish for approval. Clinicaltrials.gov shows the following polysomnographic sleep study:

Polysomnography Study of MK6096 in Patients With Primary Insomnia (6096-011)(COMPLETED) Condition: Primary Insomnia
Interventions: Drug: MK6096 2.5 mg and placebo; Drug: Comparator: MK6096 5 mg and placebo; Drug: Comparator: MK6096 10 mg and placebo; Drug: Comparator: MK6096 20 mg and placebo